AEON AEON Biopharma
- 1.705
- +0.175+11.44%
AEON Biopharma News
Express News | AEON Biopharma Inc - Termination of Migraine Study and Ole Study Will Allow Company to Conserve Cash While It Evaluates Its Strategic Options
Express News | AEON Biopharma Inc - Delivered Notice to Ppd, Inc. to Discontinue Company's Phase 2 Double Blind Study of Abp-450 in Treatment of Migraine
Express News | AEON Biopharma Inc - Appointed Marc Forth as Principal Financial Officer, Effective as of May 17, 2024
Express News | AEON Biopharma Inc - Termination of Peter Reynolds as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of Co
AEON Biopharma Is Maintained at Buy by HC Wainwright & Co.
AEON Biopharma Is Maintained at Buy by HC Wainwright & Co.
Analysts Are Bullish on These Healthcare Stocks: AEON Biopharma (AEON), Palatin Technologies (PTN)
Express News | AEON Biopharma, Inc. : H.c. Wainwright Cuts Target Price to $6 From $18
AEON Biopharma | 10-Q: Quarterly report
Express News | AEON Biopharma Q1 2024 Adj EPS $(3.17) Misses $(0.31) Estimate
Express News | AEON Biopharma Inc - Qtrly Shr Loss $3.17
Press Release: AEON Biopharma Reports First Quarter 2024 Financial Results
AEON Biopharma Reports First Quarter 2024 Financial Results -- Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary e
AEON Biopharma | 10-K/A: Annual report (Amendment)
AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner
Express News | AEON Biopharma Provides Update on Development Pipeline
Express News | HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $18 Price Target
AEON Biopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 990.91% HC Wainwright & Co. → $18 Reiterates Buy → Buy 04/17/2024 990.91% HC Wainwright & Co. →
Maintaining Buy on AEON Biopharma: Potential of ABP-450 Despite Phase 2 Setback
US Equity Markets Close Higher Friday Following Weak Jobs Report
US equity markets ended higher Friday after a weak jobs report raised bets on interest rate cuts. * Nonfarm payrolls rose by 175,000 in April, well below expectations for an increase of 240,000 jobs,
Ardelyx ARDX Earnings; AEON Biopharma AEON Phase 2 Fail
Sector Update: Health Care
Health care stocks were mixed late Friday afternoon with the NYSE Health Care Index shedding 0.2% and the Health Care Select Sector SPDR Fund (XLV) rising 0.2%. The iShares Biotechnology ETF (IBB) cli
Analysis
Price Target
No Data
